secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0000950170-25-100891
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q2 revenue $156.8M down 14% YoY; net loss includes $91.7M convertible note charge
--------------------------------------------------------------------------------

- Consolidated revenue $156.8M vs $182.2M in Q2 2024; net loss $148.4M ($0.19/share) vs $10.3M loss ($0.01) prior year, including $91.7M non-recurring convertible note expense.
- Diagnostics revenue $101.1M (-22% YoY) on lower clinical test volume from BioReference asset sale; operating loss improved to $18.2M from $26.6M.
- Pharmaceuticals revenue $40.7M (flat); operating loss $28.7M vs $24.8M, driven by higher R&D for pipeline programs.
- Board authorized additional $100M share repurchase, total capacity $200M; $58.5M repurchased through June 30.
- FDA approved 4Kscore Test without DRE; Merck Phase 1 EBV vaccine and multiple pipeline programs advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000095017025100891/0000950170-25-100891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000095017025100891/opk-20250731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-100891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer